360 related articles for article (PubMed ID: 17942755)
1. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
3. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
[TBL] [Abstract][Full Text] [Related]
5. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J
Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
[TBL] [Abstract][Full Text] [Related]
9. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Melton LJ; Bradwell AR; Clark RJ; Larson DR; Plevak MF; Dispenzieri A; Katzmann JA
Blood; 2005 Aug; 106(3):812-7. PubMed ID: 15855274
[TBL] [Abstract][Full Text] [Related]
11. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
[No Abstract] [Full Text] [Related]
12. Immunoglobulin free light chains and solitary plasmacytoma of bone.
Dingli D; Kyle RA; Rajkumar SV; Nowakowski GS; Larson DR; Bida JP; Gertz MA; Therneau TM; Melton LJ; Dispenzieri A; Katzmann JA
Blood; 2006 Sep; 108(6):1979-83. PubMed ID: 16741249
[TBL] [Abstract][Full Text] [Related]
13. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
Snozek CL; Katzmann JA; Kyle RA; Dispenzieri A; Larson DR; Therneau TM; Melton LJ; Kumar S; Greipp PR; Clark RJ; Rajkumar SV
Leukemia; 2008 Oct; 22(10):1933-7. PubMed ID: 18596742
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
17. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
Kastritis E; Terpos E; Moulopoulos L; Spyropoulou-Vlachou M; Kanellias N; Eleftherakis-Papaiakovou E; Gkotzamanidou M; Migkou M; Gavriatopoulou M; Roussou M; Tasidou A; Dimopoulos MA
Leukemia; 2013 Apr; 27(4):947-53. PubMed ID: 23183429
[TBL] [Abstract][Full Text] [Related]
18. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
19. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
[TBL] [Abstract][Full Text] [Related]
20. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]